Full FDA hold derails clinical study of Fulcrum drug in a no good, very bad week for sickle cell R&D
The roller-coaster ride of highs and lows at Cambridge, MA-based Fulcrum Therapeutics just took a sickening plunge.
Weeks after using some upbeat results to set the stage for a $125 million raise — no easy feat in this market — the Fulcrum team got hit with a full clinical hold on one of their top drugs. And the news ripped up a chunk of market value that sent shares $FULC tumbling more than 50% Friday morning.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters